Microangiopathy and visual deficits characterize the retinopathy of a spontaneously hypertensive rat model with type 2 diabetes and metabolic syndrome

Hypertension Research

Volumn 34, Issue 1, 2011, Pages 103-112

  Huber, Matthias ^a   Heiduschka, Peter ^b   Ziemssen, Focke ^b   Bolbrinker, Juliane ^a   Kreutz, Reinhold ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

electroretinography; histology; metabolic syndrome; rat; retina

Indexed keywords

CHOLESTEROL; GLUCOSE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; TRIACYLGLYCEROL;

A WAVE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B WAVE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ELECTRORETINOGRAPHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HISTOPATHOLOGY; IN VIVO STUDY; LIGHT INTENSITY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MICROANGIOPATHY; MORPHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSCILLATORY POTENTIAL; PHENOTYPE; RAT; RETINOPATHY; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION; VASCULARIZATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; HYPERTENSION; MALE; METABOLIC SYNDROME X; OBESITY; RATS; RATS, INBRED SHR; RETINA; RISK FACTORS; VISION DISORDERS;

EID: 78650911634     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.168     Document Type: Article

References (65)

1. Cheung N, Wong TY. Diabetic retinopathy and systemic vascular complications. Prog Retin Eye Res 2008; 27: 161-176.
2. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
3. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44: 156-163.
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713.
5. Silva KC, Pinto CC, Biswas SK, De Faria JB, De Faria JM. Hypertension increases retinal inflammation in experimental diabetes: a possible mechanism for aggravation of diabetic retinopathy by hypertension. Curr Eye Res 2007; 32: 533-541.
6. Silva KC, Pinto CC, Biswas SK, Souza DS, De Faria JB, De Faria JM. Prevention of hypertension abrogates early inflammatory events in the retina of diabetic hypertensive rats. Exp Eye Res 2007; 85: 123-129.
7. Pinto CC, Silva KC, Biswas SK, Martins N, De Faria JB, De Faria JM. Arterial hypertension exacerbates oxidative stress in early diabetic retinopathy. Free Radic Res 2007; 41: 1151-1158.
8. Silva KC, Rosales MA, Biswas SK, Lopes de Faria JB, Lopes de Faria JM. Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes 2009; 58: 1382-1390.
9. Misra A, Kumar S, Kishore VN, Kumar A. The role of lipids in the development of diabetic microvascular complications: implications for therapy. Am J Cardiovasc Drugs 2003; 3: 325-338.
10. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001: 285: 2486-2497.
12. Koletsky S. Obese spontaneously hypertensive rats-a model for study of atherosclerosis. Exp Mol Pathol 1973; 19: 53-60.
13. Velasque MT, Bhathena SJ, Hansen CT. Leptin and its relation to obesity and insulin in the SHR/N-corpulent rat, a model of type II diabetes mellitus. Int J Exp Diabetes Res 2001; 2: 217-223.
14. Bhathena SJ, Ali AA, Haudenschild C, Latham P, Ranich T, Mohamed AI, Hansen CT, Velasquez MT. Dietary flaxseed meal is more protective than soy protein concentrate against hypertriglyceridemia and steatosis of the liver in an animal model of obesity. J Am Coll Nutr 2003; 22: 157-164.
15. Michaelis OE, Patrick DH, Hansen CT, Canary JJ, Werner RM, Carswell N. Insulin-independent diabetes mellitus (type II). Spontaneous hypertensive/NIH-corpulent rat. Am J Pathol 1986; 123: 398-400.
16. Striffler JS, Bhathena SJ, Michaelis OE, Campbell JD, Hansen CT, Scalbert E, Thibault N, Velasquez MT. Long-term effects of perindopril on metabolic parameters and the heart in the spontaneously hypertensive/NIH-corpulent rat with non-insulin-dependent diabetes mellitus and hypertension. Metabolism 1998; 47: 1199-1204.
17. Gross ML, Ritz E, Schoof A, Adamczak M, Koch A, Tulp O, Parkman A, El-Shakmak A, Szabo A, Amann K. Comparison of renal morphology in the Streptozotocin and the SHR/ N-cp models of diabetes. Lab Invest 2004; 84: 452-464.
18. Velasquez MT, Bhathena SJ, Ranich T, Schwartz AM, Kardon DE, Ali AA, Haudenschild CC, Hansen CT. Dietary flaxseed meal reduces proteinuria and ameliorates nephropathy in an animal model of type II diabetes mellitus. Kidney Int 2003; 64: 2100-2107.
19. Marette A, Deshaies Y, Collet AJ, Tulp O, Bukowiecki LJ. Major thermogenic defect associated with insulin resistance in brown adipose tissue of obese diabetic SHR/N-cp rats. Am J Physiol 1991; 261 (2 Part 1): E204-E213.
20. Kondo T, Vicent D, Suzuma K, Yanagisawa M, King GL, Holzenberger M, Kahn CR. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest 2003; 111: 1835-1842.
21. Doi K. Studies on the mechanism of the diabetogenic activity of streptozotocin and on the ability of compounds to block the diabetogenic activity of streptozotocin (author's transl). Nippon Naibunpi Gakkai Zasshi 1975; 51: 129-147.
22. Havel PJ, Uriu-Hare JY, Liu T, Stanhope KL, Stern JS, Keen CL, Ahren B. Marked and rapid decreases of circulating leptin in streptozotocin diabetic rats: reversal by insulin. Am J Physiol 1998; 274 (5 Part 2): R1482-R1491.
23. Wu-Peng XS, Chua Jr SC, Okada N, Liu SM, Nicolson M, Leibel RL. Phenotype of the obese Koletsky (f) rat due to Tyr763Stop mutation in the extracellular domain of the leptin receptor (Lepr): evidence for deficient plasma-to-CSF transport of leptin in both the Zucker and Koletsky obese rat. Diabetes 1997; 46: 513-518.
24. Kreutz R, Kovacevic L, Schulz A, Rothermund L, Ketteler M, Paul M. Effect of high NaCl diet on spontaneous hypertension in a genetic rat model with reduced nephron number. J Hypertens 2000; 18: 777-782.
25. Polley EH, Walsh C. A technique for flat embedding and en face sectioning of the mammalian retina for autoradiography. J Neurosci Methods 1984; 12: 57-64.
26. Robison Jr WG, Laver NM, Jacot JL, Glover JP. Sorbinil prevention of diabeticlike retinopathy in the galactose-fed rat model. Invest Ophthalmol Vis Sci 1995; 36: 2368-2380.
27. Mori A, Saito M, Sakamoto K, Narita M, Nakahara T, Ishii K. Stimulation of prostanoid IP and EP(2) receptors dilates retinal arterioles and increases retinal and choroidal blood flow in rats. Eur J Pharmacol 2007; 570: 135-141.
28. Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep 2006; 6: 479-483.
29. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625.
30. Frank RN. Diabetic retinopathy. N Engl J Med 2004; 350: 48-58.
31. Bronson SK, Reiter CE, Gardner TW. An eye on insulin. J Clin Invest 2003; 111: 1817-1819.
32. Li Q, Zemel E, Miller B, Perlman I. NADPH diaphorase activity in the rat retina during the early stages of experimental diabetes. Graefes Arch Clin Exp Ophthalmol 2003; 241: 747-756.
33. Goto R, Doi M, Ma N, Semba R, Uji Y. Contribution of nitric oxide-producing cells in normal and diabetic rat retina. Jpn J Ophthalmol 2005; 49: 363-370.
34. Hammes HP. Pericytes and the pathogenesis of diabetic retinopathy. Horm Metab Res 2005; 37(Suppl 1): 39-43.
35. Kaur C, Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res 2008; 27: 622-647.
36. Cogan DG, Toussaint D, Kuwabara T. Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol 1961; 66: 366-378.
37. Hammes HP, Lin J, Wagner P, Feng Y, vom HF, Krzizok T, Renner O, Breier G, Brownlee M, Deutsch U. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 2004; 53: 1104-1110.
38. Cunha-Vaz J, Bernardes R. Nonproliferative retinopathy in diabetes type 2. Initial stages and characterization of phenotypes. Prog Retin Eye Res 2005; 24: 355-377.
39. Bhutto IA, Amemiya T. Vascular changes in retinas of spontaneously hypertensive rats demonstrated by corrosion casts. Ophthalmic Res 1997; 29: 12-23.
40. Baleanu D, Ritt M, Harazny J, Heckmann J, Schmieder RE, Michelson G. Wall-to-lumen ratio of retinal arterioles and arteriole-to-venule ratio of retinal vessels in patients with cerebrovascular damage. Invest Ophthalmol Vis Sci 2009; 50: 4351-4359.
41. Heckenlively JR, Arden GB. Principles and Practice of Clinical Electrophysiology of Vision. St Louis: MO, CV Mosby, 1991.
42. Bringmann A, Pannicke T, Grosche J, Francke M, Wiedemann P, Skatchkov SN, Osborne NN, Reichenbach A. Muller cells in the healthy and diseased retina. Prog Retin Eye Res 2006; 25: 397-424.
43. Reichenbach A, Wurm A, Pannicke T, Iandiev I, Wiedemann P, Bringmann A. Muller cells as players in retinal degeneration and edema. Graefes Arch Clin Exp Ophthalmol 2007; 245: 627-636.
44. Bringmann A, Pannicke T, Biedermann B, Francke M, Iandiev I, Grosche J, Wiedemann P, Albrecht J, Reichenbach A. Role of retinal glial cells in neurotransmitter uptake and metabolism. Neurochem Int 2009; 54: 143-160.
45. Hancock HA, Kraft TW. Oscillatory potential analysis and ERGs of normal and diabetic rats. Invest Ophthalmol Vis Sci 2004; 45: 1002-1008.
46. Kohzaki K, Vingrys AJ, Bui BV. Early inner retinal dysfunction in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 2008; 49: 3595-3604.
47. Layton CJ, Safa R, Osborne NN. Oscillatory potentials and the b-wave: partial masking and interdependence in dark adaptation and diabetes in the rat. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1335-1345.
48. Shirao Y, Kawasaki K. Electrical responses from diabetic retina. Prog Retin Eye Res 1998; 17: 59-76.
49. Bresnick GH, Palta M. Predicting progression to severe proliferative diabetic retino-pathy. Arch Ophthalmol 1987; 105: 810-814.
50. Bui BV, Armitage JA, Tolcos M, Cooper ME, Vingrys AJ. ACE inhibition salvages the visual loss caused by diabetes. Diabetologia 2003; 46: 401-408.
51. Phipps JA, Fletcher EL, Vingrys AJ. Paired-flash identification of rod and cone dysfunction in the diabetic rat. Invest Ophthalmol Vis Sci 2004; 45: 4592-4600.
52. Phipps JA, Yee P, Fletcher EL, Vingrys AJ. Rod photoreceptor dysfunction in diabetes: activation, deactivation, and dark adaptation. Invest Ophthalmol Vis Sci 2006; 47: 3187-3194.
53. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, Melena J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res 2004; 23: 91-147.
54. Anan F, Takayuki M, Takahashi N, Nakagawa M, Eshima N, Saikawa T, Yoshimatsu H. Diabetic retinopathy is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. Hypertens Res 2009; 32: 299-305.
55. Wilkinson-Berka JL, Miller AG. Update on the treatment of diabetic retinopathy. ScientificWorldJournal 2008; 8: 98-120.
56. Okuno T, Oku H, Sugiyama T, Ikeda T. Electroretinographic study of spontaneously diabetic Torii rats. Doc Ophthalmol 2008; 117: 191-196.
57. Chakrabarti S, Sima AA. Endothelin-1 and endothelin-3-like immunoreactivity in the eyes of diabetic and non-diabetic BB/W rats. Diabetes Res Clin Pract 1997; 37: 109-120.
58. Hammes HP, Klinzing I, Wiegand S, Bretzel RG, Cohen AM, Federlin K. Islet transplantation inhibits diabetic retinopathy in the sucrose-fed diabetic Cohen rat. Invest Ophthalmol Vis Sci 1993; 34: 2092-2096.
59. Kakehashi A, Saito Y, Mori K, Sugi N, Ono R, Yamagami H, Shinohara M, Tamemoto H, Ishikawa SE, Kawakami M, Kanazawa Y. Characteristics of diabetic retinopathy in SDT rats. Diabetes Metab Res Rev 2006; 22: 455-461.
60. Ktorza A, Bernard C, Parent V, Penicaud L, Froguel P, Lathrop M, Gauguier D. Are animal models of diabetes relevant to the study of the genetics of non-insulin-dependent diabetes in humans? Diabetes Metab 1997; 23(Suppl 2): 38-46.
61. Matsubara H, Kuze M, Sasoh M, Ma N, Furuta M, Uji Y. Time-dependent course of electroretinograms in the spontaneous diabetic Goto-Kakizaki rat. Jpn J Ophthalmol 2006; 50: 211-216.
62. Matsui K, Ohta T, Oda T, Sasase T, Ueda N, Miyajima K, Masuyama T, Shinohara M, Matsushita M. Diabetes-associated complications in Spontaneously Diabetic Torii fatty rats. Exp Anim 2008; 57: 111-121.
63. Matsuura T, Yamagishi S, Kodama Y, Shibata R, Ueda S, Narama I. Otsuka Long-Evans Tokushima fatty (OLETF) rat is not a suitable animal model for the study of angiopathic diabetic retinopathy. Int J Tissue React 2005; 27: 59-62.
64. Yagil C, Barak A, Ben-Dor D, Rosenmann E, Bernheim J, Rosner M, Segev Y, Weksler-Zangen S, Raz I, Yagil Y. Nonproteinuric diabetes-associated nephropathy in the Cohen rat model of type 2 diabetes. Diabetes 2005; 54: 1487-1496.
65. Rodriguez-Fontal M, Kerrison JB, Alfaro DV, Jablon EP. Metabolic control and diabetic retinopathy. Curr Diabetes Rev 2009; 5: 3-7.